Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Research & Development (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Research & Development for 6 consecutive years, with $55.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 18.6% to $55.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $261.4 million, a 18.08% decrease, with the full-year FY2025 number at $261.4 million, down 18.08% from a year prior.
  • Research & Development was $55.4 million for Q4 2025 at Relay Therapeutics, down from $68.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $92.0 million in Q2 2024 to a low of $30.6 million in Q1 2021.
  • A 5-year average of $66.5 million and a median of $67.7 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 108.38% in 2021, then plummeted 30.54% in 2025.
  • Relay Therapeutics' Research & Development stood at $51.9 million in 2021, then rose by 29.61% to $67.3 million in 2022, then rose by 15.19% to $77.5 million in 2023, then dropped by 12.16% to $68.1 million in 2024, then fell by 18.6% to $55.4 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Research & Development are $55.4 million (Q4 2025), $68.3 million (Q3 2025), and $63.9 million (Q2 2025).